Interventional Cardiology

Renal Denervation is probably the biggest buzzphrase in new therapies right now, given the size of the problem it purports to address. Medtronic has seen more promising data published at ESC, suggesting patients treated with its Symplicity™ system benefit from sustained and meaningful BP reduction at 18 months

Medtronic’s Arctic Front Advance™ Cryoablation System now delivers cold therapy to a larger area more evenly, the company claiming that this will aid cardiologists in delivering cardiac ablation therapy.

Following promising early clinical data CardioFocus has announced that its technology will be highlighted in two presentations during the forthcoming European Society of Cardiology Congress in Munich.

Medtronic has announced CE mark approval for two new CRT devices which automatically adapt to patients’ electrical rhythms, improving response to life-saving therapy.

Boston Scientific Corporation has received CE Mark approval for use of its MRI compatible INGENIO™ and ADVANTIO™ pacemakers

Vascular robotics company Corindus Vascular Robotics, has announced FDA 510(k) clearance has been granted for its CorPath 200 System to be used in percutaneous coronary interventions (PCI).

US researchers have found that the irregular heart rhythms of atrial fibrillation are caused by small electrical localised sources or “hotspots” inside the heart called focal impulses or rotors. Now they can map these rotors and ablate them with a degree of accuracy which seems to render results which are twice as good as previously achieved.

Crux Biomedical has announced FDA clearance for its novel Vena Cava Filter which uniquely features bi-directional retrieval via either the femoral or jugular vein access.

Israeli company BioControl Medical has announced U.S. FDA approval to begin the second phase of INOVATE-HF (INcrease Of VAgal TonE in Heart Failure), a global, multi-centre, investigational device exemption (IDE) clinical study of the company’s CardioFit® system for heart failure.

New Sorin study evaluates sensitivity and positive predictive value of Sleep Apnea Monitoring (SAM) feature in implantable pacemakers.

Initial findings from new study suggest successful delivery of PICSO® catheter and administration of PICSO® treatment designed to improve myocardial perfusion following primary PCI is sustained for the 90-minute study goal in first-three STEMI patients.

Impressive new data from a sizeable study population suggests that OrbusNeich’s clever pro-healing Genous™ stent may perform as well without dual antiplatelet therapy as it does with it.

A few days ago we covered the story of Claret Medical’s first-in-human study using its original CE Pro embolic capture device. At the time we felt there were a few unanswered questions, so went back to Claret for some more information. This after all is a very promising looking device with genuine patient welfare consequences.

A new clinical study suggests endoscopic ablation for Atrial fibrillation generates good results with a durable outcome and a short learning curve for operators.

Neurological protection against emboli following TAVI is highly desirable, so Claret Medical’s early clinical experience in which over 50% of filter deployments resulted in capture of debris is reason for optimism.

CardiaQ Valve Technologies has waited for the moment when its percutaneous mitral valve was first deployed in man, and it has now announced that’s occurred in what is believed to be a world first and a clinical milestone.